RUBIN PAUL D 4
4 · BioAge Labs, Inc. · Filed Feb 19, 2026
Research Summary
AI-generated summary of this filing
BioAge (BIOA) CMO Paul Rubin Receives 110,000-Share Award
What Happened
Paul D. Rubin, Chief Medical Officer of BioAge Labs, was granted a derivative award for 110,000 shares on 2026-02-17. The grant is reported at $0.00 per share (no cash paid or proceeds) and is recorded as an "A" (award/grant) transaction rather than an open-market purchase or sale. This is a compensation award and not an immediate sale.
Key Details
- Transaction date: 2026-02-17; filing date: 2026-02-19 (filed timely).
- Amount: 110,000 derivative shares reported at $0.00 per share (total reported value $0).
- Shares owned after transaction: not specified in the filing.
- Transaction code: A (award/grant); reported as a derivative acquisition.
- Footnote: Award vests 1/48th per month (monthly tranches), with the first tranche vested on Feb 1, 2026, subject to Rubin’s continued service on each vesting date.
Context
This was a standard equity compensation award to an executive, not an open-market buy or sale. Derivative awards like this typically vest over time to align incentives; they do not necessarily indicate immediate bullish or bearish trading by the insider. No cashless exercise, tax-withholding, or sale was reported in this filing.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-02-17+110,000→ 110,000 totalExercise: $19.63Exp: 2036-02-16→ Common Stock (110,000 underlying)
Footnotes (1)
- [F1]The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2026, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.